期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2021; 21 (9)
Background: Cancer patients are more vulnerable to Coronavirus disease-2019 (COVID-19) and have a higher risk of adverse outcomes than the general pop......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2021; 21 (8)
Introduction: As a protein-based biomaterial for potential cancer targeting delivery, apoferritin has recently attracted interest. Areas covered: In t......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2021; 21 (8)
Introduction Toll-like receptor-9(TLR9) can recognize the foreign unmethylated CpG DNA, and thus intrigue a strong Th1 response which plays a crucial ......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2021; 21 (7)
Background: Abnormal BUB1B expression has been proven to be related to the poor prognosis of various tumors. This meta-analysis aimed to identify the ......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2021; 21 (9)
Introduction: Surufatinib (also known as HMPL-012, sulfatinib) is a novel oral tyrosine kinase inhibitor (TKI), which has the dual activity of anti-an......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, ; ()
Purpose: This study aims to uncover potential biomarkers associated with cutaneous melanoma (CM) metastasis. Methods: The mRNA and microRNA (miRNA) ex......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2021; 21 (1)
Objectives: Extranodal natural/killer T-cell lymphoma (ENKTL) is a rare subtype of T cell non-Hodgkin's lymphoma. Current clinical prognostic models f......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2020; 20 (12)
Background Prostate cancer (PC) is the most common non-cutaneous malignancy among men in the western world. However, heterogeneity remains a pressing ......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2020; 20 (5)
Introduction: Ovarian carcinoma (OC) is the leading cause of death in women with gynecologic cancers. Most patients are diagnosed at an advanced stage......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2020; 20 (6)
Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curable strategy for acute lymphoblastic leukemia (ALL), especia......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2019; 19 (2)
Introduction: Epigenetic modification without DNA sequence mutation plays an important role in cancer development. Some small molecular inhibitors tar......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2019; 19 (6)
Objectives: To investigate the impact of EGFR mutations on the efficacy of definitive chemoradiotherapy (CRT) in patients with locally advanced unrese......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2019; 19 (7)
Background: Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is a potential detection method for bladder cancer. Many studie......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2019; 19 (8)
Introduction: The poor prognosis for patients with esophageal cancer (EC) requires evolving current treatment regimens. Immune checkpoint inhibitors s......
期刊： EXPERT REVIEW OF ANTICANCER THERAPY, 2019; 19 (9)
Introduction: Human chondrosarcomas (CS; a malignant cartilage-forming bone tumor) respond poorly to chemotherapy and radiation treatment, resulting i......
